Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004206010 | Cervix | CC | wound healing | 109/2311 | 422/18723 | 1.84e-14 | 1.57e-11 | 109 |
GO:001081010 | Cervix | CC | regulation of cell-substrate adhesion | 69/2311 | 221/18723 | 8.57e-14 | 5.69e-11 | 69 |
GO:00315898 | Cervix | CC | cell-substrate adhesion | 96/2311 | 363/18723 | 1.48e-13 | 8.85e-11 | 96 |
GO:000701510 | Cervix | CC | actin filament organization | 109/2311 | 442/18723 | 4.92e-13 | 2.45e-10 | 109 |
GO:009013210 | Cervix | CC | epithelium migration | 90/2311 | 360/18723 | 2.45e-11 | 6.11e-09 | 90 |
GO:00016679 | Cervix | CC | ameboidal-type cell migration | 110/2311 | 475/18723 | 2.66e-11 | 6.36e-09 | 110 |
GO:001063110 | Cervix | CC | epithelial cell migration | 89/2311 | 357/18723 | 3.72e-11 | 8.54e-09 | 89 |
GO:003297010 | Cervix | CC | regulation of actin filament-based process | 96/2311 | 397/18723 | 4.00e-11 | 8.54e-09 | 96 |
GO:009013010 | Cervix | CC | tissue migration | 90/2311 | 365/18723 | 5.42e-11 | 1.05e-08 | 90 |
GO:190290310 | Cervix | CC | regulation of supramolecular fiber organization | 92/2311 | 383/18723 | 1.49e-10 | 2.48e-08 | 92 |
GO:004578510 | Cervix | CC | positive regulation of cell adhesion | 101/2311 | 437/18723 | 1.96e-10 | 3.08e-08 | 101 |
GO:190332010 | Cervix | CC | regulation of protein modification by small protein conjugation or removal | 66/2311 | 242/18723 | 2.31e-10 | 3.46e-08 | 66 |
GO:190382910 | Cervix | CC | positive regulation of cellular protein localization | 72/2311 | 276/18723 | 3.20e-10 | 4.46e-08 | 72 |
GO:007265910 | Cervix | CC | protein localization to plasma membrane | 73/2311 | 284/18723 | 4.95e-10 | 6.73e-08 | 73 |
GO:000989610 | Cervix | CC | positive regulation of catabolic process | 109/2311 | 492/18723 | 5.26e-10 | 6.99e-08 | 109 |
GO:003295610 | Cervix | CC | regulation of actin cytoskeleton organization | 86/2311 | 358/18723 | 5.90e-10 | 7.51e-08 | 86 |
GO:003139610 | Cervix | CC | regulation of protein ubiquitination | 59/2311 | 210/18723 | 5.90e-10 | 7.51e-08 | 59 |
GO:004325410 | Cervix | CC | regulation of protein-containing complex assembly | 96/2311 | 428/18723 | 2.91e-09 | 3.05e-07 | 96 |
GO:001063210 | Cervix | CC | regulation of epithelial cell migration | 72/2311 | 292/18723 | 4.52e-09 | 4.43e-07 | 72 |
GO:00512359 | Cervix | CC | maintenance of location | 78/2311 | 327/18723 | 5.18e-09 | 4.92e-07 | 78 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0513120 | Cervix | CC | Shigellosis | 69/1267 | 247/8465 | 7.64e-08 | 1.03e-06 | 6.10e-07 | 69 |
hsa0453020 | Cervix | CC | Tight junction | 49/1267 | 169/8465 | 1.87e-06 | 1.78e-05 | 1.05e-05 | 49 |
hsa0466612 | Cervix | CC | Fc gamma R-mediated phagocytosis | 31/1267 | 97/8465 | 1.78e-05 | 1.42e-04 | 8.40e-05 | 31 |
hsa0407110 | Cervix | CC | Sphingolipid signaling pathway | 35/1267 | 121/8465 | 5.70e-05 | 3.93e-04 | 2.32e-04 | 35 |
hsa049336 | Cervix | CC | AGE-RAGE signaling pathway in diabetic complications | 25/1267 | 100/8465 | 5.64e-03 | 1.88e-02 | 1.11e-02 | 25 |
hsa05131110 | Cervix | CC | Shigellosis | 69/1267 | 247/8465 | 7.64e-08 | 1.03e-06 | 6.10e-07 | 69 |
hsa04530110 | Cervix | CC | Tight junction | 49/1267 | 169/8465 | 1.87e-06 | 1.78e-05 | 1.05e-05 | 49 |
hsa0466613 | Cervix | CC | Fc gamma R-mediated phagocytosis | 31/1267 | 97/8465 | 1.78e-05 | 1.42e-04 | 8.40e-05 | 31 |
hsa0407113 | Cervix | CC | Sphingolipid signaling pathway | 35/1267 | 121/8465 | 5.70e-05 | 3.93e-04 | 2.32e-04 | 35 |
hsa0493313 | Cervix | CC | AGE-RAGE signaling pathway in diabetic complications | 25/1267 | 100/8465 | 5.64e-03 | 1.88e-02 | 1.11e-02 | 25 |
hsa05131 | Colorectum | AD | Shigellosis | 109/2092 | 247/8465 | 1.09e-11 | 2.44e-10 | 1.55e-10 | 109 |
hsa04530 | Colorectum | AD | Tight junction | 76/2092 | 169/8465 | 5.49e-09 | 9.69e-08 | 6.18e-08 | 76 |
hsa04666 | Colorectum | AD | Fc gamma R-mediated phagocytosis | 46/2092 | 97/8465 | 9.10e-07 | 1.22e-05 | 7.77e-06 | 46 |
hsa04071 | Colorectum | AD | Sphingolipid signaling pathway | 43/2092 | 121/8465 | 4.83e-03 | 2.28e-02 | 1.45e-02 | 43 |
hsa051311 | Colorectum | AD | Shigellosis | 109/2092 | 247/8465 | 1.09e-11 | 2.44e-10 | 1.55e-10 | 109 |
hsa045301 | Colorectum | AD | Tight junction | 76/2092 | 169/8465 | 5.49e-09 | 9.69e-08 | 6.18e-08 | 76 |
hsa046661 | Colorectum | AD | Fc gamma R-mediated phagocytosis | 46/2092 | 97/8465 | 9.10e-07 | 1.22e-05 | 7.77e-06 | 46 |
hsa040711 | Colorectum | AD | Sphingolipid signaling pathway | 43/2092 | 121/8465 | 4.83e-03 | 2.28e-02 | 1.45e-02 | 43 |
hsa051314 | Colorectum | MSS | Shigellosis | 94/1875 | 247/8465 | 6.82e-09 | 1.34e-07 | 8.23e-08 | 94 |
hsa046664 | Colorectum | MSS | Fc gamma R-mediated phagocytosis | 45/1875 | 97/8465 | 9.30e-08 | 1.56e-06 | 9.55e-07 | 45 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PRKCE | SNV | Missense_Mutation | | c.2180N>T | p.Gly727Val | p.G727V | Q02156 | protein_coding | deleterious(0) | probably_damaging(0.963) | TCGA-73-4676-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | PD |
PRKCE | SNV | Missense_Mutation | | c.1346N>T | p.Asp449Val | p.D449V | Q02156 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-78-7152-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
PRKCE | SNV | Missense_Mutation | novel | c.1706N>A | p.Gly569Glu | p.G569E | Q02156 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-21-1079-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
PRKCE | SNV | Missense_Mutation | | c.913N>A | p.Asp305Asn | p.D305N | Q02156 | protein_coding | tolerated(0.15) | benign(0.156) | TCGA-33-4589-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PRKCE | SNV | Missense_Mutation | | c.2063N>T | p.Arg688Leu | p.R688L | Q02156 | protein_coding | deleterious(0) | possibly_damaging(0.848) | TCGA-43-5668-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Other, specify in notesMAGE3-AS15-NSC-003 | clinical | PD |
PRKCE | SNV | Missense_Mutation | novel | c.1729G>A | p.Glu577Lys | p.E577K | Q02156 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-43-A56V-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Chemotherapy | carboplatin | PD |
PRKCE | SNV | Missense_Mutation | novel | c.1394N>G | p.Lys465Arg | p.K465R | Q02156 | protein_coding | tolerated(0.31) | benign(0.003) | TCGA-56-A4BY-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
PRKCE | SNV | Missense_Mutation | | c.929N>T | p.Pro310Leu | p.P310L | Q02156 | protein_coding | deleterious(0.01) | benign(0.273) | TCGA-60-2726-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
PRKCE | SNV | Missense_Mutation | novel | c.2045A>G | p.Lys682Arg | p.K682R | Q02156 | protein_coding | tolerated(0.33) | benign(0.005) | TCGA-98-A53I-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | navelbine | SD |
PRKCE | SNV | Missense_Mutation | | c.483N>T | p.Arg161Ser | p.R161S | Q02156 | protein_coding | deleterious(0) | benign(0.41) | TCGA-NC-A5HD-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5581 | PRKCE | SERINE THREONINE KINASE, DRUGGABLE GENOME, KINASE, ION CHANNEL, TRANSCRIPTION FACTOR, ENZYME | | PHORBOL MYRISTATE ACETATE | PHORBOL MYRISTATE ACETATE | 22579485 |
5581 | PRKCE | SERINE THREONINE KINASE, DRUGGABLE GENOME, KINASE, ION CHANNEL, TRANSCRIPTION FACTOR, ENZYME | | INGENOL MEBUTATE | | |
5581 | PRKCE | SERINE THREONINE KINASE, DRUGGABLE GENOME, KINASE, ION CHANNEL, TRANSCRIPTION FACTOR, ENZYME | | [3H]-PHORBOL 12,13-DIBUTYRATE | CHEMBL27768 | 24794745 |
5581 | PRKCE | SERINE THREONINE KINASE, DRUGGABLE GENOME, KINASE, ION CHANNEL, TRANSCRIPTION FACTOR, ENZYME | | KAI-1455 | | |
5581 | PRKCE | SERINE THREONINE KINASE, DRUGGABLE GENOME, KINASE, ION CHANNEL, TRANSCRIPTION FACTOR, ENZYME | inhibitor | CHEMBL608533 | MIDOSTAURIN | |
5581 | PRKCE | SERINE THREONINE KINASE, DRUGGABLE GENOME, KINASE, ION CHANNEL, TRANSCRIPTION FACTOR, ENZYME | inhibitor | 249565629 | SOTRASTAURIN | |
5581 | PRKCE | SERINE THREONINE KINASE, DRUGGABLE GENOME, KINASE, ION CHANNEL, TRANSCRIPTION FACTOR, ENZYME | inhibitor | 178102576 | CHELERYTHRINE | |
5581 | PRKCE | SERINE THREONINE KINASE, DRUGGABLE GENOME, KINASE, ION CHANNEL, TRANSCRIPTION FACTOR, ENZYME | inhibitor | CHEMBL3545332 | CEP-2563 | |
5581 | PRKCE | SERINE THREONINE KINASE, DRUGGABLE GENOME, KINASE, ION CHANNEL, TRANSCRIPTION FACTOR, ENZYME | | BRYOSTATIN | BRYOSTATIN | |
5581 | PRKCE | SERINE THREONINE KINASE, DRUGGABLE GENOME, KINASE, ION CHANNEL, TRANSCRIPTION FACTOR, ENZYME | | radiotherapy | | 25054431 |